BONE BIOLOGICS CORP (BBLG)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.57+1.86%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Bone Biologics focuses on bone regeneration with a unique medical device. The company recently issued debt to support growth. Analysts expect EPS losses to improve from -$1.93 in 2026 to -$1.26 in 2027. The stock has gained 22.5% over the past 63 days, showing some positive momentum.
The company is loss-making with no revenue estimates and negative free cash flow. EPS is expected to remain negative through 2027. The biotech sector is risky and the company faces high uncertainty. Debt issuance may increase financial risk.
The market currently prices in continued losses and no revenue growth. Our view is cautious given the improving EPS estimates but ongoing losses and lack of revenue visibility.
Breaks if: Free cash flow yield remains below -0.6% beyond FY27
Breaks if: EPS loss does not improve beyond -1.93 USD per share by FY27
Breaks if: Revenue remains at zero through FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and faces elevated risks, but it operates in a sector with potential tailwinds that could support its long-term thesis.
The market appears to have low expectations for BBLG, given its recent financial struggles compared to peers. The valuation reflects a loss-making status, indicating that investors are cautious about future performance.
Management is focused on advancing clinical programs and maintaining capital discipline, which are critical as the company extends its operating runway. However, the recent financial performance has been weak, and there is a high probability of missing earnings in the near term.
The future of BBLG hinges on several factors, including management's ability to meet clinical milestones and the overall health of the healthcare sector. Additionally, guidance cuts or worsening economic indicators could negatively impact sentiment.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, BBLG's prospects will depend on its execution of key priorities and external market conditions. Not investment advice.